ATE386740T1 - Beta-3 adrenergische agonisten - Google Patents

Beta-3 adrenergische agonisten

Info

Publication number
ATE386740T1
ATE386740T1 AT02789238T AT02789238T ATE386740T1 AT E386740 T1 ATE386740 T1 AT E386740T1 AT 02789238 T AT02789238 T AT 02789238T AT 02789238 T AT02789238 T AT 02789238T AT E386740 T1 ATE386740 T1 AT E386740T1
Authority
AT
Austria
Prior art keywords
beta
adrenergic agonists
sub
imidazo
group containing
Prior art date
Application number
AT02789238T
Other languages
German (de)
English (en)
Inventor
Jolie Bastian
Gerd Ruehter
Daniel Sall
Theo Schotten
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE386740T1 publication Critical patent/ATE386740T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02789238T 2001-11-20 2002-11-12 Beta-3 adrenergische agonisten ATE386740T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33403101P 2001-11-20 2001-11-20

Publications (1)

Publication Number Publication Date
ATE386740T1 true ATE386740T1 (de) 2008-03-15

Family

ID=23305278

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02789238T ATE386740T1 (de) 2001-11-20 2002-11-12 Beta-3 adrenergische agonisten

Country Status (8)

Country Link
US (4) US7071208B2 (enExample)
EP (1) EP1448561B1 (enExample)
JP (1) JP2005518357A (enExample)
AT (1) ATE386740T1 (enExample)
AU (1) AU2002353844A1 (enExample)
DE (1) DE60225174T2 (enExample)
ES (1) ES2299618T3 (enExample)
WO (1) WO2003044017A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1421078B1 (en) * 2001-08-14 2006-09-27 Eli Lilly And Company Indole derivatives as beta-3 adrenergic agonists for the treatment of type 2 diabetes
JP2005518357A (ja) * 2001-11-20 2005-06-23 イーライ・リリー・アンド・カンパニー ベータ３アドレナリンアゴニスト
DE60204718T2 (de) * 2001-11-20 2006-05-18 Eli Lilly And Co., Indianapolis 3-substituierte oxindol beta 3 agonisten
JP4618250B2 (ja) * 2003-12-23 2011-01-26 アステラス製薬株式会社 アミノアルコール誘導体
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
DE102004050952A1 (de) * 2004-10-18 2006-04-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung von Beschwerden, die mit krankhaften Veränderungen oder Irritationen der Prostata verbunden sind
JP2008100916A (ja) * 2005-01-24 2008-05-01 Dainippon Sumitomo Pharma Co Ltd インドール類およびそれを含む医薬組成物
JP4864982B2 (ja) * 2005-12-27 2012-02-01 エフ．ホフマン−ラ ロシュ アーゲー アリール−イソオキサゾール−４−イル−イミダゾ［１，５−ａ］ピリジン誘導体
WO2007137954A1 (en) 2006-05-31 2007-12-06 F. Hoffmann-La Roche Ag Aryl-4-ethynyl-isoxazole derivatives
MX2009014001A (es) 2007-06-22 2010-01-28 Hoffmann La Roche Derivados de isoxazol-imidazol.
US7902201B2 (en) 2007-12-04 2011-03-08 Hoffmann-La Roche Inc. Isoxazolo-pyrazine derivatives
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
EP2229383B1 (en) 2007-12-04 2017-01-18 F. Hoffmann-La Roche AG Isoxazolo-pyrazine derivatives
TW201033201A (en) 2009-02-19 2010-09-16 Hoffmann La Roche Isoxazole-isoxazole and isoxazole-isothiazole derivatives
US8389550B2 (en) 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
US8222246B2 (en) 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
US20100280019A1 (en) 2009-04-30 2010-11-04 Roland Jakob-Roetne Isoxazoles
JP5466292B2 (ja) 2009-05-05 2014-04-09 エフ．ホフマン−ラ ロシュ アーゲー イソオキサゾール−ピリジン誘導体
EP2427459B1 (en) 2009-05-05 2016-09-28 F. Hoffmann-La Roche AG Isoxazole-thiazole derivatives as gaba a receptor inverse agonists for use in the treatment of cognitive disorders
SG175333A1 (en) 2009-05-05 2011-12-29 Hoffmann La Roche Isoxazole-pyrazole derivatives
KR101701533B1 (ko) 2009-05-05 2017-02-13 에프. 호프만-라 로슈 아게 아이속사졸-피리다진 유도체
CA2757412C (en) 2009-05-07 2016-04-05 F. Hoffmann-La Roche Ag Isoxazole-pyridine derivatives as gaba modulators
US8785435B2 (en) 2011-10-20 2014-07-22 Hoffmann-La Roche Inc. Solid forms
CN111108105B (zh) 2017-09-22 2023-03-31 朱比兰特埃皮帕德有限公司 作为pad抑制剂的杂环化合物
KR102782563B1 (ko) 2017-10-18 2025-03-14 주빌런트 에피파드 엘엘씨 Pad 억제제로서의 이미다조-피리딘 화합물
AU2018362046B2 (en) 2017-11-06 2023-04-13 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
HUE067265T2 (hu) 2017-11-24 2024-10-28 Jubilant Episcribe Llc Heterociklusos vegyületek mint PRMT5 inhibitorok
EP3765453A1 (en) 2018-03-13 2021-01-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
WO2023114844A1 (en) * 2021-12-15 2023-06-22 Delix Therapeutics, Inc. Imidazopyridine psychoplastogens and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH624395A5 (enExample) 1976-01-08 1981-07-31 Ciba Geigy Ag
CA1116598A (en) 1977-07-13 1982-01-19 William T. Comer 3-indolyl-tertiary butylaminopropanols
US4234595A (en) 1977-07-13 1980-11-18 Mead Johnson & Company 3-Indolyl-tertiary butylaminopropanols
US4314943A (en) 1977-07-13 1982-02-09 Mead Johnson & Company Heterocyclic substituted aryloxy 3-indolyl-tertiary butylaminopropanols
JPS6010021B2 (ja) 1979-01-31 1985-03-14 田辺製薬株式会社 新規ベンジルアルコ−ル誘導体及びその製法
DE3423429A1 (de) 1984-06-26 1986-01-02 Beiersdorf Ag, 2000 Hamburg Substituierte phenoxyalkylaminopropanole, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen
DE3426419A1 (de) 1984-07-18 1986-01-23 Boehringer Mannheim Gmbh, 6800 Mannheim Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US4728651A (en) 1985-10-24 1988-03-01 Hoechst-Roussel Pharmaceuticals Inc. Antihypertensive thieno-isoxazoles and -pyrazoles
GB8528633D0 (en) 1985-11-21 1985-12-24 Beecham Group Plc Compounds
US5451677A (en) 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
NO303782B1 (no) 1994-03-23 1998-08-31 Sankyo Co Tiazolidin- og oksazolidinderivater og farmas°ytiske preparater inneholdende slike, samt deres anvendelse til fremstilling av medikamenter
US5705515A (en) 1994-04-26 1998-01-06 Merck & Co., Inc. Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
WO1997046556A1 (en) 1996-06-07 1997-12-11 Merck & Co., Inc. OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
US5808080A (en) 1996-09-05 1998-09-15 Eli Lilly And Company Selective β3 adrenergic agonists
ES2171839T3 (es) 1996-09-05 2002-09-16 Lilly Co Eli Analogos de carbazol como agonistas adrenergicos selectivos de beta3.
US6011048A (en) 1997-01-28 2000-01-04 Merck & Co., Inc. Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity
PL334833A1 (en) 1997-01-28 2000-03-27 Merck & Co Inc Thiazolobenzenosulphonamides as beta3 agonists for treating diabetes and obesity
AUPP796798A0 (en) 1998-12-30 1999-01-28 Fujisawa Pharmaceutical Co., Ltd. New compound
JP2003055344A (ja) * 1999-01-29 2003-02-26 Dainippon Pharmaceut Co Ltd ３，７−ジ置換インドール誘導体及びそれを含有する医薬組成物
AU6050000A (en) 1999-07-22 2001-02-13 Eli Lilly And Company Improved method of treating type ii diabetes and obesity
WO2001035947A2 (en) 1999-11-15 2001-05-25 Eli Lilly And Company Treating wasting syndromes with aryloxy propanolamines
WO2001036412A1 (en) 1999-11-15 2001-05-25 Eli Lilly And Company Process for the preparation of aryloxy propanolamines
US6420365B1 (en) * 2000-01-18 2002-07-16 Neurogen Corporation Imidazopyridines and related derivatives as selective modulators of bradykinin B2 receptors
HRP20030018A2 (en) 2000-07-13 2003-04-30 Lilly Co Eli Beta3 adrenergic agonists
IL154928A0 (en) 2000-11-10 2003-10-31 Lilly Co Eli 3-substituted oxindole beta 3 agonists
ATE325119T1 (de) 2001-08-14 2006-06-15 Lilly Co Eli 3-substituierte oxindol-beta-3-agonisten
EP1421078B1 (en) 2001-08-14 2006-09-27 Eli Lilly And Company Indole derivatives as beta-3 adrenergic agonists for the treatment of type 2 diabetes
DE60204718T2 (de) 2001-11-20 2006-05-18 Eli Lilly And Co., Indianapolis 3-substituierte oxindol beta 3 agonisten
JP2005518357A (ja) 2001-11-20 2005-06-23 イーライ・リリー・アンド・カンパニー ベータ３アドレナリンアゴニスト

Also Published As

Publication number Publication date
US20050020618A1 (en) 2005-01-27
EP1448561A1 (en) 2004-08-25
ES2299618T3 (es) 2008-06-01
DE60225174T2 (de) 2009-02-12
JP2005518357A (ja) 2005-06-23
US20060142328A1 (en) 2006-06-29
US7241772B2 (en) 2007-07-10
US7265127B2 (en) 2007-09-04
DE60225174D1 (de) 2008-04-03
US20060142329A1 (en) 2006-06-29
US20060142327A1 (en) 2006-06-29
US7253181B2 (en) 2007-08-07
US7071208B2 (en) 2006-07-04
AU2002353844A1 (en) 2003-06-10
WO2003044017A1 (en) 2003-05-30
EP1448561B1 (en) 2008-02-20

Similar Documents

Publication Publication Date Title
DE60225174D1 (de) Beta-3 adrenergische agonisten
DE60037345D1 (de) Pyrroloi2,3-d pyrimidinderivate enthaltende Zusammensetzungen
BR0015963A (pt) Compostos de uréia antagonistas receptor muscarìnico, composições farmacêuticas compreendendo tais compostos e método de preparação destes compostos
ATE309245T1 (de) 5-amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3- d)pyrimidin-derivate
NO20043022L (no) 5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister
IT1308627B1 (it) Composizioni fluoroelastomeriche.
IT1308628B1 (it) Composizioni fluoroelastomeriche.
NO20013001D0 (no) 2,3,4,4A-tetrahydro-1H-pyrazino(1,2-A)kinoksalin-5(6H)on- derivater som er 5HT2C-agonister
DK1444215T3 (da) 1,2,4-Thiadiazoliumderivater som melanocortinreceptormodulatorer
NO20010603D0 (no) 2-substituert-1-piperidylbenzimidazol forbindelser som ORL 1- reseptor agonister
DK1337518T3 (da) Piperazinylpyrazinforbindelser som antagonister for serotonin-5-HT2-receptoren
NO20015477L (no) 4,5,6,7-tetrahydroindazolderivater som antitumormidler
EA200100773A1 (ru) Замещенные 1-гетероциклические диариламины
EE200200275A (et) Immunosupressantidena kasutatavad 2,4-diaminopürimidiiniühendid
CL2004001085A1 (es) Compuestos derivados de quinolil propil piperidina, procedimiento de preparacion; compuesto intermediario; composicion farmaceutica, utiles como agentes microbianos.
ATE283857T1 (de) Imidazo(1,5-aöpyrimido)5,4-döbenz azepinderivate als gaba-a-rezeptormodulatoren
IT1319251B1 (it) Metodo per la preparazione di 5-carbossiftalide.
EA200400454A1 (ru) Мускариновые агонисты
MXPA05005198A (es) Derivados de imidazoquinolina, como ligandos del receptor a3 de adenosina.
MA27094A1 (fr) Derives triazolo-quinoline utiles en tant que ligands recepteurs d'adenosine.
DE60214408D1 (de) 5-METHOXY-8-ARYL-i1,2,4öTRIAZOLOi1,5-AöPYRIDINE DERIVATIVE ALS ADENOSIN-REZEPTOR ANTAGONISTEN
SE9702794D0 (sv) New compounds
DE60001366D1 (de) Orale zusammensetzung enthaltend perlit
CA2372664A1 (en) Substituted benzimidazole, the production thereof and the use thereof as means against parasitic protozoa
NO20034529D0 (no) 3,7-diazabicyklo(3,3,1) formuleringer samt antiarytmiforbindelser

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties